Study Stopped
Not enough participants and study funding
Quality of Life in Patients With Multiple Myeloma-validation Study
Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland
1 other identifier
observational
58
1 country
3
Brief Summary
In this study, the Myeloma Patient Outcome Scale (MyPOS) will be translated from English to German. This translated version will be quantitatively and qualitatively validated with patients with multiple myeloma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2018
Typical duration for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 15, 2018
CompletedFirst Posted
Study publicly available on registry
May 25, 2018
CompletedStudy Start
First participant enrolled
October 10, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2021
CompletedOctober 14, 2021
October 1, 2021
2.8 years
May 15, 2018
October 5, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS)
The primary outcome will be the scores on each item of the culturally-adapted Swiss-German MyPOS. Items are scored on a five-point Likert scale. For the analysis, the three subscales "Symptoms" (range: 0-52), "Emotions" (range:0-68) and "Healthcare Support" (range: 0-12) are assessed as well as the MyPOS total score (range: 0-132 ) by summing up the item scores ranging from 0-4. Higher scores reflect worse quality of life. The scores will be used to evaluate the psychometric properties of the culturally-adapted Swiss-German MyPOS: * Structural validity, * Internal consistency, * Construct validity, * Convergent and divergent validity.
upon enrollment
Study Arms (1)
MyPOS
Interventions
Patients complete the MyPOS questionnaire on quality of life
Eligibility Criteria
Patients with multiple myeloma
You may qualify if:
- informed consent as documented by signature
- confirmed histological diagnosis of multiple myeloma,
- age ≥ 18 years,
- mental capacity to give written informed consent
You may not qualify if:
- inability to communicate in German
- participation in another clinical study
- more than one cancer diagnosis
- mental illness (i.e. psychiatric diagnosis)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zurich University of Applied Scienceslead
- Kantonsspital Münsterlingencollaborator
- Kantonsspital Aaraucollaborator
- Klinik Hirslanden, Zurichcollaborator
- Celgene Corporationcollaborator
- King's College Londoncollaborator
Study Sites (3)
Kantonsspital Aarau
Aarau, Canton of Zurich, 5001, Switzerland
Kantonsspital Münsterlingen
Münsterlingen, Thurgau, 8596, Switzerland
Onkozentrum Hirslanden
Zurich, 8032, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Julia Dratva, Prof.Dr.med
Zurich University of Applied Sciences
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of health sciences research unit
Study Record Dates
First Submitted
May 15, 2018
First Posted
May 25, 2018
Study Start
October 10, 2018
Primary Completion
July 31, 2021
Study Completion
July 31, 2021
Last Updated
October 14, 2021
Record last verified: 2021-10